
Jun Jeon, MD
284 posts

Jun Jeon, MD
@junwjeon
health, tech, and biology @khoslaventures
Katılım Ocak 2016
509 Takip Edilen300 Takipçiler
Jun Jeon, MD retweetledi

AI × bio is the only field where:
— you're too slow for AI people and too fast for bio people
— you're too computational for biologists and too biological for ML folks
— tech VCs overprice you and bio VCs underprice you
You are permanently miscalibrated in every direction.
It's great actually.
English
Jun Jeon, MD retweetledi
Jun Jeon, MD retweetledi

I currently have three papers in review at "high impact" journals.
One of them has been sitting there for two years. In that time my daughter was born and learned how to walk, but apparently publishing a PDF was still not possible for me. For another one, after four months in review the editor told me they cannot find a second reviewer and asked me to suggest more reviewers. A third one sent me a message in 2026 saying the PDF I uploaded was larger than 10 MB and that I should please reupload everything to make the file smaller.
All of this just to eventually pay between 7,000 and 12,000 USD per paper so someone can officially approve that the science we do is "legitimate". Reminder: not a single reviewer will be compensated here.
I still don't understand how we as scientists can collectively be so smart when doing science and still tolerate a system like this when it comes to sharing our findings. We should move to preprints plus open review, whether human or AI, asap. So frustrated about it.
I'd suggest sharing your work on bioRxiv or medRxiv, reading and reviewing preprints when you can, and highlighting good research, especially if it is still a preprint. Try platforms like ResearchHub (that pay for peer review) and experiment with AI based reviewers for faster feedback.
Instead I read this as a proposed "revolutionary" measure:

English

round bottom wok on a non gas stove is low key revolutionary. This is actually really cool
@ImpulseLabs
Impulse@ImpulseLabs
Introducing the Impulse Wok Ring.
English
Jun Jeon, MD retweetledi

Jun Jeon, MD retweetledi

@diegoadiazg @NEJM Do you think osimertinib 1L and then doing MET inhibitor etc after if appropriate is equivalent in OS vs doing both EGFR-MET upfront? Curious what the real advantage of doing upfront would be
English

🎯 MARIPOSA: Amivantamab–Lazertinib in EGFRm NSCLC.
In 1L EGFR-mutated advanced NSCLC, amivantamab–lazertinib significantly improved OS vs osimertinib (HR 0.75; 3-yr OS 60% vs 51%). Confirms the value of dual EGFR–MET inhibition in this setting.
📖 @NEJM
DOI 👉🏻 10.1056/NEJMoa2503001
#CánCare #NSCLC #EGFR #lcsm




English

Did you know, in order to reverse admin mistake during cancer treatment, you only need these 3 things in combination = #POTUS + Secretary of HHS + a #billionaire
#healthcare #cancer #insurance #scheduling

English
Jun Jeon, MD retweetledi



















